NAME,DISTRIBUTION,DESCRIPTION,SOURCE,MEAN (IQR),used?,,,,,,,
ontxY,"LN( -3.963316,0.6457913)",CFR children <5 on TB treatment,Jenkins et al 2017,0.019 (0.012 - 0.029),Y,,,,,,,
ontxO,"LN(-4.828314,0.4817445)",CFR children 5-14 on TB treatment,Jenkins et al 2017,0.008 (0.006 - 0.011),Y,,,,,,,
hivartOR:mn,"MVN: [2.6375681, -0.5683867]","ORs of death on TB treatment, (OR HIV+ vs -) x (ART -/+): mean","Jenkins et al 2017, Dodd et al 2017",,Y,,,,,,,
hivartOR:sg,"MVN: [[0.2325509,-0.2325509],[-0.2325509,0.6367345]]","ORs of death on TB treatment, (OR HIV+ vs -) x (ART -/+): variance","Jenkins et al 2017, Dodd et al 2017",,Y,,,,,,,
notxY,"LN(-0.830113,0.08035318)",CFR children <5 without TB treatment,Jenkins et al 2017,0.436 (0.413 - 0.460),Y,,,,,,,
notxO,"LN(-1.903809,0.1285165)",CFR children 5-14 without TB treatment,Jenkins et al 2017,0.149 (0.137 - 0.162),Y,,,,,,,
notxHY,"B(77.13050,11.10817)",CFR children <5 without TB treatment (HIV+/ART-),Dodd et al 2017,0.877 (0.852 - 0.899),Y,,,,,,,
notxHO,"B(19.59083,6.89700)",CFR children 5-14 without TB treatment (HIV+/ART-),Dodd et al 2017,0.746 (0.686 - 0.800),Y,,,,,,,
notxHAY,"B(15.18683,12.87500)",CFR children <5 without TB treatment (HIV+/ART+),Dodd et al 2017,0.542 (0.478 - 0.605),Y,,,,,,,
notxHAO,"B(10.43383,11.08417)",CFR children 5-14 without TB treatment (HIV+/ART+),Dodd et al 2017,0.484 (0.412 - 0.558),Y,,,,,,,
hivpi,"LN(2.066863,0.2800718)",IRR for TB incidence given HIV+/ART- (for individuals),Dodd et al 2017,7.900 (6.540 - 9.543),Y,,,,,,,
artp,"LN(-1.203973,0.150482)",HR for TB incidence given HIV+/ART+ vs HIV+/ART-,Dodd et al 2016,0.300 (0.271 - 0.332),Y,,,,,,,
HHhivprev04,"B(55,526)",Prevalence of HIV in child HH contacts of HIV+ index case,Martinez et al 2017,0.094 (0.086 - 0.103),Y,,,,,,,
HHhivprev514,"B(54,854)",Prevalence of HIV in child HH contacts of HIV+ index case,Martinez et al 2017,0.059 (0.054 - 0.065),Y,,,,,,,
LTBI04,"B(106.7330582,193.9234438)",LTBI prevalence,Fox et al 2013,0.355 (0.336 - 0.373),Y,,,,,,,
LTBI514,"B(41.83776346,36.95275153)",LTBI prevalence,Fox et al 2013,0.531 (0.493 - 0.569),Y,,,,,,,
LTBI04hi,"B(10.62231,54.54526)",LTBI prevalence,Fox et al 2013,0.160 (0.131 - 0.192),Y,,,,,,,
LTBI514hi,"B(17.0386,75.56247)",LTBI prevalence,Fox et al 2013,0.182 (0.156 - 0.210),Y,,,,,,,
iptRR,"B(45.48834,77.45311)","RR for incident TB given IPT, age <15",Martinez et al 2018,0.369 (0.340 - 0.399),Y,,,,,,,
iptRRtstpos,"B(11.23657,113.6142)","RR for incident TB given IPT in TST+, age <15",Martinez et al 2018,0.088 (0.072 - 0.106),Y,,,,,,,
iptRRhivpos,"LN(-1.171183,0.5127492)","RR for incident TB given IPT in HIV+, age <15",Zunza et al 2017,0.310 (0.219 - 0.438),Y,,,,,,,
CFRrtx.RR,"B(11.09004,127.5355)",CFR RR-ATT when truly RR,Harausz 2018,0.078 (0.064 - 0.094),Y,,,,,,,
coprevDRkids,"LN(2.054124,0.1417502)",coprevalence in percent of HH contacts of DRTB,Shah 2017,7.800 (7.089 - 8.583),Y,,,,,,,
concord,"B(57.40241,12.09203)",concordance in DR type,Chiang 2020,0.829 (0.797 - 0.858),Y,,,,,,,
prog04,"B(5.152793,21.96717)",LTBI+ progression u5,Martinez et al 2018,0.182 (0.136 - 0.236),Y,,,,,,,
prog514,"B(4.151282,43.02238)",LTBI+ progression u5,Martinez et al 2018,0.082 (0.058 - 0.112),Y,,,,,,,358
fracSymptomatic,"B(2.936,11.744)",Fraction of contacts presumptive TB,Martinez 2017 & Sayedi 2020,0.186 (0.124 - 0.262),Y,,,,,,,
fracAE,"B(31,358)",Fraction of PT with G2 AEs,Malik 2020 & Seddon 2013,,,,,,,,,
fracSAE,"B(6,358)",Fraction of PT with G3/4 AEs,Malik 2020 & Seddon 2013,,,,,,,,,